In this paper we present a strategy for tuning the crystal morphology of pharmaceutical compounds by the appropriate choice of solvent via an optimization model. A three-stage approach involving a pre-design stage, a product design stage and a post-design experimental verification stage is presented. The pre-design stage addresses the formulation of the property constraint for crystal morphology. This involves crystallization experiments and development of property models and constraints for morphology. In the design stage various property requirements for the solvent along with crystal morphology are considered and the product design problem is formulated as a mixed integer nonlinear programming model. The design stage provides an optimal solvent/list of candidate solvents. Similar to the pre-design stage, in the post design experimental verification stage, the morphology of the crystals (precipitated from the designed solvent) is verified through crystallization experiments followed by productcharacterization via scanning electron microscopy, powder X-ray diffraction imaging and Fourier transform spectra analysis.